Company intelligence / Profile preview

Jacaranda Biosciences

San Francisco, California, United Statesjacaranda-bio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Jacaranda Biosciences is developing small molecule therapeutics aimed at preventing or halting the progression of hearing loss. Their approach targets restoration of ER stress equilibrium to address both noise-induced and drug-induced forms of ototoxicity. The company’s programs are currently in preclinical development. No clinical results have been reported yet.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of May 2025.

Beyond the preview

Go deeper on Jacaranda Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jacaranda Biosciences.

Explore the full profile